Putting the Pieces Together: Completing the Mechanism of Action Jigsaw for Sipuleucel-T

Sipuleucel-T is an autologous cellular immunotherapy that induces an immune response targeted against prostatic acid phosphatase (PAP) to treat asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC). In the phase III IMPACT study, sipuleucel-T was associated with a statistically significantly increased overall survival (OS) (median 4.1 months) versus placebo. Patients with baseline prostate-specific antigen levels in the lowest quartile (